Felix Biotechnology
YC W20San Francisco, US · Founded 2019 · 6 employees · Inactive · 3 known investors
Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
Founders & leadership· Y Combinator alumni (W20)
Investors · 3
In the news
- Cystic Fibrosis Foundation Invests in Felix Biotechnology as They Advance New Therapies Targeting Chronic Infections in Cystic Fibrosis - BioSpacebiospace.com · 2022
- Felix Biotechnology Awarded Competitive Grant from the National Science Foundation to Power Phage Engineering Platformprnewswire.com · 2021
- Felix Biotechnology - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- Felix Biotechnology announces initiation of research collaboration with Biocogent, the leading provider of high technology products to personal care and cosmetic industries.prnewswire.com · 2021
- Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections - Microbiome Times Magazinemicrobiometimes.com · 2021
- Discovering Biotech Startups: A map for Selling to Felix Biotechnologyblog.zymewire.com · 2020